바이오테크 보도자료
-
- FDA Accepts Alvotech’s BLA Supporting Interchangeability for ATV02, a High Concentration, Citrate-Free Biosimilar Candidate for Humira®
- Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has accepted...
- 2022년 03월 02일
-
- Glucophage® Is the First Oral Diabetes Treatment Approved in Europe for Use During Pregnancy
- Merck, a leading science and technology company, today announced in a European worksharing procedure (WSP) an extension to the label for metformin products in the EU - Glucophage® (metformin hydrochloride [HCL] immediate release), Glucophage XR® (...
- 2022년 03월 02일
-
- Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
- Regulatory News: This press release features multimedia. View the full release here: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Medicines Agency’s (EMA) CHMP has ...
- 2022년 02월 28일
-
- Oncocross Begins Phase I Clinical Trial of AI-Developed Drug for Sarcopenia
- Oncocross, an AI-based drug development biotech, announced that it initiated a phase I global clinical trial for ‘OC514’ targeting muscular diseases including sarcopenia. Oncocross obtained Australia’s Therapeutic Goods Administration (“TGA”) appr...
- 2022년 02월 28일
-
- GliaPharm SA and the Wyss Center Enter Collaboration to Develop New Therapies for Alzheimer’s Disease
- GliaPharm SA, a biotech company that specializes in the research and development of novel therapies to treat and prevent neurological diseases, and the Wyss Center, a non-profit organization dedicated to accelerating discoveries in neuroscience to...
- 2022년 02월 25일
-
- ASEAN Safety Sensors and Switches Market is estimated to be worth around USD 1.58 Bn in 2032: Future Market Insights
- The market for safety sensors and switches in ASEAN countries is likely to grow by more than 8%, yearly, in 2019. As depicted in a new research study of Future Market Insights (FMI), the adoption of safety sensors and switches across the ASEAN ind...
- 2022년 02월 25일
-
- Schneider Electric Acquires Renewable Energy Platform Zeigo to Expand Digital Procurement Capabilities Globally
- Schneider Electric, the leader in the digital transformation of energy management, automation, and sustainability today announced that it has acquired start-up climate-tech platform Zeigo to enhance the company’s digital capabilities in energy, su...
- 2022년 02월 23일
-
- Taro to Acquire Alchemee From Galderma
- Galderma and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced today they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company (TPC), from Galderma. The agreement between Galderma and Tar...
- 2022년 02월 23일
-
- Kaneka Eurogentec Announces the Successful Production of 25g of mRNA in One Batch
- Kaneka Eurogentec, an FDA inspected contract development and manufacturing organization (CDMO), announced today that its mRNA manufacturing facility has successfully produced a 25 g batch of mRNA for a US customer. Successful large-scale mRNA prod...
- 2022년 02월 23일
-
- European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations
- Merck, a leading science and technology company, today announced that the European Commission (EC) has approved once-daily oral TEPMETKO® (tepotinib) as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCL...
- 2022년 02월 21일
-
- Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma
- Merck, a leading science and technology company, today announced the results of an exploratory analysis from the Phase III JAVELIN Bladder 100 trial with 19 additional months of follow-up data from the initial primary analysis. This analysis reinf...
- 2022년 02월 21일
-
- Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study[1,2]
- Takeda (TSE:4502/NYSE:TAK) today announced the first six-month interim analysis results from INSPIRE, in which clinical remission[*] was observed in 65% of patients in both cohorts who were evaluated at 6 months.[1] INSPIRE is a European, observat...
- 2022년 02월 21일
전시회
